This study is a Phase 1/1b clinical trial that aims to determine the Maximally Tolerated Dose
of Losartan and Sunitinib Combination Therapy. Patients will first be accrued to the Dose
Escalation phase of the study, using a 3+3 design. Medication dosages will increase until a
maximally tolerated dose is found. Patients will then be accrued to the Dose Expansion phase
of the trial, where efficacy of pre-determined dose will be preliminarily assessed.